CymaBay Therapeutics (CBAY) Announces FDA Lifts All Clinical Holds on Seladelpar

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to CymaBay Therapeutics (CBAY) Announces FDA Lifts All Clinical Holds on Seladelpar

FDA Lifts All Clinical Holds on Seladelpar

July 23, 2020 8:00 AM EDT

Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC 

Re-initiating clinical development focusing first on Phase 3 for PBC

NEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that the Food and Drug Administration (FDA) lifted clinical holds on seladelpar for all three Investigational New Drug (IND) Applications in Nonalcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC) and Primary... More